Phase 3 Randomized 3-Month Trial with an Ongoing 3-Month Safety Extension of Fixed-Combination Brinzolamide 1%/Brimonidine 0.2%
نویسندگان
چکیده
منابع مشابه
Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension
BACKGROUND The objective of this study was to examine the safety and intraocular pressure (IOP)-lowering efficacy of a fixed combination of brinzolamide 1% + brimonidine 0.2% (BBFC) after six months of treatment in patients with open-angle glaucoma or ocular hypertension. METHODS This was a randomized, multicenter, double-masked, three-month, three-arm contribution-of-elements study with a th...
متن کاملThe Comparison of Temperament of 3-12 Month Infants of Mothers with and without Mental Health
Background & Aims: The quality of interaction between mother and infant has an important role in the formation of infant's personality, social and cognitive functions, temperament and mental health in future. The quality of this reaction is not predictable and can be improved along the time. Thus, Knowing effective variables in this area can be very beneficial in its improvement. Method: In the...
متن کامل3-month Outlook user guide
The 3-month Outlook provides an indication of temperature and rainfall conditions in the next 3 months, averaged over the UK. It is part of a suite of forecasts designed and produced on behalf of Government, for use by contingency planners, and is one of several tools used in environmental risk planning by a number of different sectors. The 3-month Outlook should not be used in isolation. It is...
متن کاملFormoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
The aim of this study was to investigate formoterol, an inhaled long-acting beta2-agonist, in patients with chronic obstructive pulmonary disease (COPD). Six-hundred and ninety-two COPD patients, mean baseline forced expiratory volume in one second (FEV1) 54%, FEV1/forced vital capacity 75% of predicted, reversibility 6.4% pred, were treated with formoterol (4.5, 9 or 18 microg b.i.d.) or place...
متن کاملLUPRON DEPOT® -3 Month 11.25 mg (leuprolide acetate for depot suspension) 3-MONTH FORMULATION
Leuprolide acetate is a long-acting GnRH analog. A single injection of LUPRON DEPOT–3 Month 11.25 mg will result in an initial stimulation followed by a prolonged suppression of pituitary gonadotropins. Repeated dosing at quarterly (LUPRON DEPOT–3 Month 11.25 mg) intervals results in decreased secretion of gonadal steroids; consequently, tissues and functions that depend on gonadal steroids for...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Ocular Pharmacology and Therapeutics
سال: 2013
ISSN: 1080-7683,1557-7732
DOI: 10.1089/jop.2012.0235